TARO-CARBAMAZEPINE SUSPENSION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

CARBAMAZEPINE

Доступна с:

TARO PHARMACEUTICALS INC

код АТС:

N03AF01

ИНН (Международная Имя):

CARBAMAZEPINE

дозировка:

100MG

Фармацевтическая форма:

SUSPENSION

состав:

CARBAMAZEPINE 100MG

Администрация маршрут:

ORAL

Штук в упаковке:

450ML

Тип рецепта:

Prescription

Терапевтические области:

MISCELLANEOUS ANTICONVULSANTS

Обзор продуктов:

Active ingredient group (AIG) number: 0108674002; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2011-05-02

Характеристики продукта

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
TARO- CARBAMAZEPINE
Carbamazepine Tablets
Tablets, 200 mg, Oral
Taro Standard
Pr
TARO- CARBAMAZEPINE CHEWABLE TABLETS
Carbamazepine Chewable Tablets
Chewable Tablets, 100 mg and 200 mg, Oral
Pr
TARO- CARBAMAZEPINE CR
Carbamazepine Extended-Release Tablets
Extended-Release Tablets, 200 mg and 400 mg, Oral
Taro Standard
Pr
TARO- CARBAMAZEPINE
Carbamazepine Oral Suspension
Oral Suspension, 100 mg / 5 mL, Oral
USP
Anticonvulsant
For Symptomatic Relief of Trigeminal Neuralgia
Antimanic
ATC code: N03AF01
Taro Pharmaceuticals Inc.
Date of Initial Authorization:
130 East Drive
May 06, 1998
Brampton, Ontario
L6T 1C1
Date of Revision:
March 3, 2022
Control No: 255034
_ TARO-CARBAMAZEPINE PRODUCT MONOGRAPH PAGE 2 OF 54_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
03/2022
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
03/2022
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations; 4.5 Missed
Dose
03/2022
7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics
03/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.......................................................................................................
2
TABLE OF CONTENTS
.........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................................
4
1
INDICATIONS
.............................................................................................................................
4
1.1
Pediatrics
...............................................................................................................................
4
1.2
Geriatrics................................................................................................................................
5
2
CONTRAINDICATIONS
......................................................................